We had detected a slightly, but significantly, higher level of plasma nitrite/nitrate in the sponstanously hypertensive rat (SHR) by using the nitric oxide (NO) analyzer (Sievers 280 NOA), which converts nitrate (including nitrate converted from nitrite) to NO. Here, we examined whether the release of NO from protein-bound dinitrosyl nonheme iron complexes (DNIC) contributes to the elevated plasma nitrate level in the SHR. The SHR and their genetic normotensive controls, WistarKyoto rats (WKY), were anesthestized and cannulized for monitoring blood pressure, collecting a blood sample, and the administration of endotoxin (lipopolysaccharide [LPS]). The nitrate levels (an indicator of NO formation) in the plasma and the aorta were measured by an NO analyzer. In addition, the relaxation of acetylcholine (ACh) in the presence or absence of N -nitro-L-arginine methyl ester (L-NAME) was also examined in thoracic aortae obtained from both strains. The slight, but significant, increase of basal nitrate levels in the plasma and aorta were observed, and the former was further enhanced in SHR treated with LPS for 3 h. In vitro, the AChinduced relaxation was attenuated in the aortae obtained from SHR. However, this difference between SHR and WKY (without LPS treatment) was abolished by treatment of rings with L-NAME (30 mol/L), suggesting that an impairment of NO formation was observed in the SHR. After rats were treated with LPS for 3 h, the ACh-induced relaxation was reduced in the WKY, but not in the SHR. In addition, a 10-fold increase of L-NAME was needed to abolish the difference in AChinduced relaxation between SHR and WKY, indicating an expression of inducible NO synthase in both strains treated with LPS. We suggest that the elevated plasma NO level in SHR may be due to the release of NO T he discovery by Furchgott and Zawadzki in 1980 of endothelium-derived relaxing factor (EDRF) 1 has now been proved to play a central role in the cardiovascular system. A few years later, the EDRF had been identified to be chemically equivalent to nitric oxide (NO) 2,3 or a biochemical congener thereof. 4 NO is produced by the conversion of the terminal guanidine nitrogen atom(s) from l-arginine into l-citrulline, or a complex molecule yielding NO. 5, 6 The importance of NO in the physio- There are numerous reports showing that endothelium-dependent relaxations of isolated vascular rings from spontaneously hypertensive rats (SHR) are impaired when compared with those from Wistar-Kyoto (WKY) rats. [13] [14] [15] These results suggest that dysfunction of the endothelium causes an abnormal relaxation, 16, 17 or a simultaneous release of endotheliumdependent contracting factor(s) decreases the relaxing activity of NO. 17, 18 Any decrease in NO generation may have a substantial effect on blood pressure and tissue blood flow.
T he discovery by Furchgott and Zawadzki in 1980 of endothelium-derived relaxing factor (EDRF) 1 has now been proved to play a central role in the cardiovascular system. A few years later, the EDRF had been identified to be chemically equivalent to nitric oxide (NO) 2, 3 or a biochemical congener thereof. 4 NO is produced by the conversion of the terminal guanidine nitrogen atom(s) from l-arginine into l-citrulline, or a complex molecule yielding NO. 5, 6 The importance of NO in the physio-logic control of blood pressure is now well established. In addition, NO also prevents the activation and adhesion of platelets and neutrophils to the endothelium, dilates vascular smooth muscle, and inhibits cell mitogenesis and proliferation. 7, 8 NO causes vascular smooth muscle relaxation by activation of soluble guanylate cyclase and by increasing cyclic guanosine 3Ј,5Ј-monophosphate (cGMP) levels, 9, 10 causing a decrease in intracellular Ca 2ϩ . Therefore, alterations in NO synthesis may be an important factor in the pathogenesis of hypertension.
It has been shown that the generation of NO from l-arginine by NO synthase (NOS) is an important autocrine and paracrine signaling pathway in the regulation of various cell functions. 7 In the vascular wall, endothelial cells express a constitutive Ca 2ϩ -calmodulin-dependent NOS (NOS III). 11 A second type of NOS (Ca 2ϩ -calmodulin-independent [NOS II]) can be expressed in smooth muscle cells and fibroblasts by cytokines such as interleukin-1␤ or tumor necrosis factor-␣, or by mechanical, viral, or bacterial injuries. 7, 12 The NOS II induced by cytokines and endotoxin (lipopolysaccharide [LPS]) produces larger amounts of NO than NOS III does.
There are numerous reports showing that endothelium-dependent relaxations of isolated vascular rings from spontaneously hypertensive rats (SHR) are impaired when compared with those from Wistar-Kyoto (WKY) rats. [13] [14] [15] These results suggest that dysfunction of the endothelium causes an abnormal relaxation, 16, 17 or a simultaneous release of endotheliumdependent contracting factor(s) decreases the relaxing activity of NO. 17, 18 Any decrease in NO generation may have a substantial effect on blood pressure and tissue blood flow.
The NO Analyzer (Sievers 280 NOA, Sievers Inc., Boulder, CO) has been developed for the direct assessment of NO level in exhaled air 19 -21 and of NO metabolites in the liquid system (eg, plasma), [22] [23] [24] and has been used extensively in recent years. [25] [26] [27] [28] This machine is more sensitive than the Griess assay and more stable than the electrode system, 29 indicating that the NO Analyzer is reliable for the detection of NO and its metabolites.
Recently, a study has shown that an overproduction of NO is involved in the interaction between macrophages or vascular smooth muscle cells and lymphocytes in SHR, suggesting a general activation of the NO synthesis system in SHR. 30 In contrast to earlier studies, Nava and colleagues have recently reported that increased activity of NOS III is observed in cardiac endothelium in SHR. 31 In addition, our previous studies also showed a basal expression of NOS II in the aorta from SHR. 32, 33 A recent study demonstrated that NO can be generated independently of NOS. 34 It proposed that NO reacts with nonheme iron to form protein-bound dinitrosyl nonheme iron complexes (DNIC) in blood vessels. Therefore, the aim of this study was to delineate the effect of NO in hypertension and to evaluate whether the release of NO from DNIC contributes to the higher plasma NO level in SHR. In this study, we examined NO metabolite levels (ie, nitrite/nitrate) in the plasma and aorta by using the NO analyzer.
MATERIALS AND METHODS
In Vivo Experiments Sixteen-week-old male SHR and WKY rats, whose stock originated from the Charles River Breeding Laboratories in Japan, were purchased from the Deparment of Laboratory Animal Science of the National Defense Medical Center. Systolic blood pressure was measured in conscious rats by the tail-cuff method using a MOD 59 tail sphygmograph (Blood Pressure Meter/Amplifier, Itic Inc., Woodland Hills, CA) every week. The systolic blood pressure of SHR and WKY rats was 189 Ϯ 11 mm Hg (n ϭ 36) and 144 Ϯ 7 mm Hg (n ϭ 20), respectively. Animals were anesthetized by intraperitoneal injection of a combination of urethane (0.6 g/kg) and chloral hydrate (0.4 g/kg). The trachea was cannulated to facilitate respiration and rectal temperature was maintained at 37°C with a homeothermic blanket (Harvard Apparatus Ltd., South Natick, MA). The right femoral artery was cannulated and connected to a pressure transducer (P23ID, Statham, Oxnard, CA) for the measurement of phasic and mean arterial blood pressure (MAP) and heart rate, which were displayed on a Grass model 7D polygraph recorder (Grass Instruments, Quincy, MA). The left femoral vein was cannulated for the administration of Escherichia coli LPS (5 mg/kg). Please note that the injection of LPS in rats was further done to examine the effect of basal expression of iNOS in SHR on hemodynamic changes. Upon completion of the surgical procedure, cardiovascular parameters were allowed to stabilize for 20 min. After recording baseline hemodynamic parameters, animals received either saline (ie, sham-operated) or LPS and were monitored for 3 h.
Determination of Levels of Plasma Nitrate
Before and at 1, 2, and 3 h after injection of LPS, 0.25 mL of blood was collected from a catheter placed in the femoral artery. Any blood withdrawn was immediately replaced by intravenous (iv) injection of an equal amount of saline. The blood sample was centrifuged (7200 g for 3 min) to prepare plasma and plasma was kept in a Ϫ70°C freezer. At a later stage, plasma samples were thawed and deproteinized by incubating them with 95% ethanol (4°C) for 30 min. These samples were subsequently centrifuged for 5 min at 14,000 g. The nitrate concentration in plasma depicted in this study is actually the total nitrite and nitrate concentration in plasma. In this method nitrate is reduced to NO via nitrite. The amounts of nitrate in the plasma (2 L) were measured by adding a reducing agent (0.8% VCl 3 in 1 N HCl) to the purge vessel to convert nitrate to NO, which was stripped from the plasma using a helium purge gas. The NO was then drawn into the Sievers Nitric Oxide Analyzer (Sievers 280 NOA, Sievers Inc., Boulder, CO). Nitrate concentrations were calculated by comparison with standard solutions of sodium nitrate (Sigma Chemical Co., St. Louis, MO).
Determination of Levels of Aortic Nitrate
Thoracic aortae were obtained from SHR and WKY without LPS treatment. Two rats' aortae from each group were pooled together (ie, n ϭ 1) to measure the nitrate in the vascular smooth muscle. After they were cleaned of fat and connective tissues, aortae were frozen in liquid nitrogen and stored for no more than 2 weeks at Ϫ80°C before assay. At a later stage, frozen samples were thawed and cut into pieces and these samples were homogenized on ice with a polytron PT MR 3000 homogenizer (Kinematic AG, Littau) in a buffer composed of (mmol/L): Tris-HCl 50, EDTA 0.1, EGTA 0.1, 2-mercaptoethanol 12, and phenylmethylsulphonyl fluoride 1 (pH 7.4). Aortic homogenates were then further incubated with N-acetyl-l-cysteine (an agent that decomposes the dinitrosyl nonheme iron complexes, 30 mmol/L) 34 for 10 min. This reaction was stopped with adding 1% trichloroacetic acid (TCA, 4°C) and subsequently these samples were centrifuged for 7 min at 13,000 g. The amounts of nitrate in the supernatant (30 L, approximately 60 g protein) were injected into the NO analyzer as described earlier.
Organ Bath Experiments
At the end of the in vivo experiments, rats were exsanguinated and the thoracic aorta was excised and placed in cold physiologic salt solution (PSS; 4°C). Control aortae were also obtained from untreated (ie, sham-operated) rats. Fat and connective tissues were trimmed from the aorta and aortae were then cut into rings (3 to 4 mm in width). While preparing these rings, care was taken to avoid damaging the endothelium. The rings were left to equilibrate for 1 h under an optimal resting tension of 2.0 g (in the WKY group) or 1.8 g (in the SHR group) and washed every 15 min. Before the relaxation studies, rings were challenged twice with phenylephrine (PE, 0.3 mol/L) to ensure the reproducibility of the observed contractile response. Drugs were removed from the bath by several washes with PSS, and the tension was allowed to return to baseline. Again, rings were contracted with PE (0.3 mol/L). When maximal stable contractile responses were reached, acetylcholine (ACh, 1 nmol/L to 1 mol/L) was added to the bath in a cumulative manner. In addition, the relaxation of ACh was also examined in the presence of the NOS inhibitor N -nitro-l-arginine methyl ester (L-NAME, 30 to 300 mol/L).
Chemicals Acetylcholine chloride, bacterial lipopolysaccharide (E. coli serotype 0127:B8), phenylephrine HCl, L-NAME, N-acetyl-l-cysteine, sodium nitrate, and urethane were purchased from Sigma Chemical Co. Vanadium chloride (VCl 3 ) was obtained from Aldrich Chemical Co. (Milwaukee, WI). (Scheffé's test) , except for the aortic nitrate study, which was analyzed by unpaired Student's t test. A value of P Ͻ .05 was considered to be statistically significant.
Statistical Analysis
All values in the figures and text are expressed as mean Ϯ SEM of n observations, where n represents the number of animals or experiments performed. Statistical evaluation was performed by using ANOVA followed by a multiple comparison test
RESULTS

Effects of LPS on Blood Pressure and Plasma Nitrate
Although rats were anesthetized, the MAP was higher in the SHR than in the WKY. The injection of saline instead of LPS did not cause any significant changes of MAP during the experimental period (eg, WKY: 114 Ϯ 3 mm Hg at time 0 v 108 Ϯ 5 mm Hg at 3 h, n ϭ 8, P Ͼ .05; SHR: 154 Ϯ 8 mm Hg at time 0 v 144 Ϯ 8 at 3 h, n ϭ 12, P Ͼ .05) in the sham-operated groups ( Figure  1A , left panel). In contrast, the injection of LPS resulted in a fall of MAP after 1 h until the end of the experiment (ie, at 3 h after LPS) in both SHR and WKY ( Figure 1A, right panel) . The dose of LPS used in this study caused only a mild hypotension (ϳ30 mm Hg fall at 3 h) in the WKY rats; it had a much greater hypotensive effect (ϳ61 mm Hg fall at 3 h) in the SHR. In other words, at 3 h after LPS the MAP values between WKY and SHR were not significantly different from each other. In addition, four of 24 SHR (which were not included in our MAP data) had a severe hypotension and died before the experimental period, whereas none of the WKY rats exhibited this effect. Figure 1B (left panel) shows that basal levels of plasma nitrate were 12.3 Ϯ 1.3 and 7.4 Ϯ 0.4 mol/L in SHR and WKY, respectively, significantly higher in SHR than in WKY. In addition, the operation did not cause a significant rise of plasma nitrate, as there were no significant changes during the experimental period in both strains ( Figure 1B, left panel) . After treatment of rats with LPS, the increment of plasma nitrate was in a time-dependent manner in both strains ( Figure  1B, right panel) . However, the ability of LPS to increase nitrite was greater in SHR than in WKY (ie, at 1 h, twofold v 1.6-fold; at 3 h, 12.6-fold v 9.4-fold).
Changes of Nitrate Levels in the Aorta
To examine the basal level of nitrate in the blood vessel wall, the aorta was obtained from rats without LPS treatment. Figure 2 shows that the basal level of aortic nitrate is higher in SHR than in WKY.
Effects of L-NAME on ACh-Induced Relaxations
In the sham-operated groups, ACh evoked a dose-dependent relaxation in endothelium-intact aortic rings obtained from WKY and SHR (Figure 3, left panel) . However, the relaxation caused by ACh was reduced in the SHR, compared with WKY. In the presence of 30 mol/L L-NAME, the difference of ACh-induced relaxation between SHR and WKY was abolished. It is noted that in rats treated with LPS, the dose-response curve of ACh was shifted to the right in rings obtained from WKY rats, but not in those from SHR ( Figure 3 , left and right panels). Interestingly, at the same concentration of L-NAME (ie, 30 mol/L), the difference in ACh-induced relaxation between SHR and WKY was not significantly affected. However, this difference was abolished by increasing the concentration of L-NAME to 300 mol/L (Figure 3, right panel) . In this experiment, we observed that there were two preparations from the SHR (in response to ACh) resistant to 300 mol/L L-NAME, whereas they needed 1 mol/L L-NAME to abolish the ACh relaxation (data not shown).
DISCUSSION
We have demonstrated that the intravenous injection of LPS (5 mg/kg) caused a mild hypotension in normotensive rats, but induced a more severe hypotensive effect in SHR. Using treatment with LPS, the plasma levels of nitrate were significantly increased in both strains and were significantly higher in SHR. Interestingly, a slight, but significantly, higher basal level of plasma nitrate was observed in the SHR. This higher basal level of plasma nitrate in SHR could be due to an increased activity of NOS III in the cardiac endothelium 31 or to a basal expression of NOS II in the aorta.
32,33 Although we did not have good evidence showing that this difference is important from a biologic standpoint, a recent study has demonstrated that NO function in the vascular beds can be enhanced in the hypertensive state and provides a compensatory mechanism to keep the blood pressure and peripheral resistance at lower levels. 35 This was also supported by results showing that NO blockade produced an exaggerated pressor response in SHR compared with WKY. 36, 37 Based on the fact that the mechanism of NO-induced relaxation in the aorta is not different from that in the resistant blood vessels at the level of the smooth muscle cell, and that the production of NO contributes mainly to the relaxation in large conduitory blood vessels rather than in the resistance vessels, 38, 39 we therefore examined the effect of NO in the aorta instead of in the resistance vessels. Our in vitro studies manifest that an impaired relaxation to ACh was found in aortic rings from SHR, as other studies reported, 16 -18 suggesting that dysfunction of the endothelium causes an abnormal relaxation 16, 17 or that a simultaneous release of endothelium-dependent contracting factor(s) decreases the relaxing activity of NO. 17, 18 Here, we show that the difference caused by ACh in both strains was abolished by the NOS inhibitor L-NAME, suggesting that this difference between WKY and SHR comes from NO. This result argues strongly against the possibility that NOS III activity is increased in the aortic endothelium, as reported in the cardiac endothelium of SHR. 31 Thus, it is more likely that a higher basal plasma nitrate level is due to a basal expression of NOS II in the aorta from SHR.
Indeed, the production of NO in cultured SHR vascular smooth muscle cells was greater than that in WKY. 30, 40 Here, we have also demonstrated that the level of NO release from DNIC was higher in the aorta from SHR. This may contribute to a larger expression of the soluble guanylate cyclase in the smooth muscle from SHR than from WKY. 41 The treatment of rats with LPS did not further impair the ACh-induced relaxation in SHR ex vivo, but it significantly attenuated that response in WKY. This is consistent with previous studies showing that bacterial LPS produces a selective diminution of the endothelium-dependent vasodilator actions in an E. coli endotoxemia model. 42 Because the endothelium-dependent vasodilatation has been impaired in the SHR, the treatment of SHR with LPS may not be able to further reduce NOS III activity, as we demonstrated in our previous studies. 33 Suprisingly, the treatment of aortic rings with the NOS inhibitor L-NAME (30 mol/L, which completely inhibited ACh-induced relaxation in the sham-operated group) only partially shifted the dose-response curve of ACh to the right in both strains treated with LPS, indicating an expression of NOS II in the endothelium. The NOS inhibitor L-NAME, at a lower concentration (Ͻ30 mol/L), is more selective for NOS III 43 or neuronal NOS, 44 whereas at a higher concentration (Ͼ300 mol/L), it also inhibits NOS II activity. 43, 44 It seems that the expression of endothelial NOS II, which is more resistant to the NOS inhibitor L-NAME, is inhibited by a higher concentration of L-NAME, as it has abolished the ACh-induced relaxation. Although there are no studies showing that endothelial NOS II is responsible for the relaxation caused by ACh, it appears to be a possible mechanism for this interpretation. Furthermore, the difference of ACh-induced relaxation between WKY and SHR caused by LPS may also be due to the synthesis of NO (presumably via NOS II), as the NOS inhibitor L-NAME (at a higher concentration) could abolish that difference between WKY and SHR.
Although this study is largely confirmatory, it would be interesting to investigate possible changes in signal tranduction and molecular regulation of NOS in hypertension in future studies using biochemical or molecular biologic techniques. For instance, Scott and colleagues have suggested that a decreased activity of NOS III is linked to an increased activity of NOS II in LPS-incubated tissues. 45 In addition, we have proposed a compensatory relationship between NOS III and NOS II in the development of hypertension in SHR. 33 Thus, we conclude that the enhanced basal formation of NO may be attributed to the release of NO from DNIC in the SHR, which then provides a compensatory effect to combat the hypertensive state.
